Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Janssen Licenses Ionis Drug for GI Autoimmune Disease | Contract Pharma

What are you searching for?

Sign in
Breaking News

Janssen Licenses Ionis Drug for GI Autoimmune Disease

Represents first oral antisense drug acting locally in the GI tract

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Janssen Biotech, Inc. has licensed Ionis Pharmaceuticals’ IONIS-JBI1-2.5Rx, an oral antisense drug for the treatment of a GI autoimmune disease, for $10 million. Janssen will assume all global development, regulatory and commercialization responsibilities after Ionis completes the IND-enabling studies.
 
Ionis is eligible to receive as much as $800 million in development, regulatory and sales milestones and license fees for three programs, as well as royalties on sales from any product that is successfully commercialized. 
 
“IONIS-JBI1-2.5Rx is the first antisense drug to enter development as part of Ionis’ collaboration with Janssen to discover and develop orally administered, locally acting RNA-targeted therapeutics for autoimmune diseases in the gastrointestinal tract.  We are very pleased to have rapidly advanced this first drug candidate into development within a year and a half of initiating our collaboration with Janssen,” said B. Lynne Parshall, chief operating officer at Ionis Pharmaceuticals.  “This new drug further expands our technology’s reach into a new therapeutic setting and a new route of delivery.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics